The State of Extrahepatic siRNA Delivery: Which targeting ligands (peptides, aptamers, antibodies, small molecules) are showing the most convincing functional extrahepatic delivery for siRNA?

Potency & Durability Outside the Liver: Why do CNS, muscle, heart, and lung still require higher doses or more frequent dosing, and what chemistry or structural innovations are closing that gap?

Cracking the Delivery Bottleneck: Which strategies (endosomolytic peptides, pH‑responsive linkers, receptor‑cycling ligands, ionizable scaffolds, protein corona mitigations) are most likely to improve cytosolic delivery of siRNA. How can we

Barriers to Implementation: What are the primary hurdles—chemical stability, scale-up CMC, or unpredictable translatability PK/PD/tolerability—that prevent us from moving these "next-gen" conjugate strategies into the clinic more rapidly

AI/ML for Predictive siRNA Biopackaging: How can AI help predict tissue tropism, receptor engagement, safety, and barrier navigation for complex siRNA conjugates before entering animal studies?